Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Recruiting

Phase 2

Pioglitazone & MetforminPioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Sponsor:

University of Minnesota

Code:

NCT05727761

Conditions

Oral Leukoplakia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

pioglitazone-metformin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-24. This information was provided to ClinicalTrials.gov by University of Minnesota on 2025-12-24.